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NOVEL AGENTS IN THE TREATMENT OF LUNG CANCER
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Approximately 10 to 15% of patients with non-small cell lung
cancer have tumors that depend on activation of the epidermal
growth factor receptor (EGFR), as evidenced by mutations in EGFR.
In these patients, there is often an initial dramatic response to
treatment with the first-generation EGFR tyrosine kinase inhibitors
(TKIs) erlotinib or gefitinib. A small number of patients with EGFR
mutations have primary resistance to erlotinib and gefitinib, and
most patients who initially respond to treatment with erlotinib or
gefitinib will develop resistance to first-generation EGFR TKIs. The
problems with both primary and acquired resistance to erlotinib and
gefitinib support the need for development of additional agents that
inhibit EGFR signaling in such patients. This is an overview of three
representative second-generation EGFR TKIs. HKI-272, a second-
generation irreversible EGFR TKI that also inhibits HER2, has
completed accrual of a phase II trial in both untreated patients and
patients with acquired resistance to erlotinib or gefitinib. XL647 is
a reversible inhibitor of EGFR, HER2, and vascular epidermal
growth factor receptor. Preclinical work shows that XL647 can
inhibit cell lines bearing mutated forms of EGFR that have been
associated with acquired resistance. BIBW2992 is an irreversible
EGFR TKI that also inhibits HER2 and vascular epidermal growth
factor receptors. In vitro work shows that this compound inhibits
wild-type EGFR, EGFR exon 19 deletion, EGFR L858R, and EGFR
T790M, the mutation associated with acquired resistance. The pre-
liminary results from phase I and phase II trials for BIBW-2992 and
XL647 are discussed.
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Of the nearly 200,000 people diagnosed with lung cancereach year in the United States, approximately 20,000 to
30,000 have non-small cell lung cancer (NSCLC) with so-
matic mutations in the epidermal growth factor receptor gene
(EGFR). These changes in EGFR, most commonly mutations
in exon 19 or exon 21, which encode the kinase domain of
EGFR, have been previously identified in patients with initial
radiographic response to gefitinib and erlotinib.1–3 More re-
cently, introduction of the two most common mutations, EGFR
exon 19 deletion and EGFR L858R, into transgenic mice has led
to tumor formation, demonstrating that expression of these
constitutively activated forms of EGFR are sufficient for trans-
formation and required for maintenance of these tumors.4,5
Both retrospective and prospective data demonstrate
that most patients with NSCLC and somatic mutations in
EGFR derive clinical benefit from inhibition of EGFR by the
first-generation EGFR tyrosine kinase inhibitors (TKIs), ge-
fitinib and erlotinib (reviewed in6). Retrospective series show
an overall response rate for erlotinib and gefitinib of 16 to
83% in patients with EGFR mutations. Prospective trials that
have selected only patients with EGFR mutations for treat-
ment with erlotinib or gefitinib have shown response rates of
65 to 82%. In contrast, in unselected patients with NSCLC,
there was a 9% response rate to erlotinib, with a 2-month
improvement in overall survival when compared with pa-
tients treated with placebo.7 Among patients treated with
erlotinib and gefitinib, the clinical characteristics which have
been associated with response to erlotinib or gefitinib are
Asian ethnicity and patients who are never smokers.8–10
Despite the excellent results for many patients, patients
with an initial response to erlotinib or gefitinib will generally
develop acquired resistance to these drugs. While the median
time to progression is approximately 12 months, some pa-
tients have time to progressions of 2 to 3 years.11,12 Acquired
resistance to EGFR inhibitors occurs because of either selec-
tion of a secondary EGFR mutation (EGFR T790M is the
most common), which allows continued EGFR signaling
despite the presence of erlotinib or gefitinib, or amplification
of the oncogene MET.13–18 In addition, unknown mechanisms
of acquired resistance cause 30 to 50% of patients to develop
clinical acquired resistance.
There is no standard treatment for patients with ac-
quired resistance to erlotinib or gefitinib. Laboratory and
clinical evidence suggests that further inhibition of the EGFR
pathway, and potentially additional pathways, may overcome
acquired resistance to erlotinib or gefitinib. In cell lines with
EGFR T790M mutations that are resistant to erlotinib or
gefitinib, treatment with irreversible inhibitors of EGFR, such
as EKB-569 and HKI-272, leads to apoptosis.4,17 Clinically,
preliminary evidence suggests that patients who have devel-
oped clinical acquired resistance to erlotinib or gefitinib may
Memorial Sloan-Kettering Cancer Center, New York, New York.
Disclosure: Dr. Riely was a compensated consultant for Genentech and
Boehringer-Ingelheim. Dr. Riely has received travel expenses and hon-
orarium from Boehringer-Ingelheim.
Address for correspondence: Gregory J. Riely, MD, PhD, Thoracic Oncology
Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New
York, NY 10021. E-mail: rielyg@mskcc.org
Copyright © 2008 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/08/0306-0146
Journal of Thoracic Oncology • Vol. 3, No. 6, Supplement 2, June 2008S146
continue to benefit from continued EGFR inhibition with
erlotinib or gefitinib.19 Such patients may benefit from the
addition of cytotoxic chemotherapy along with continued
treatment with erlotinib or gefitinib.
A number of second-generation EGFR inhibitors are
being studied and hold the potential to prevent the develop-
ment of acquired resistance or overcome acquired resistance
in patients previously treated with gefitinib or erlotinib. This
overview highlights available preclinical information and the
early clinical development of representative second-genera-
tion EGFR TKIs.
HKI-272
HKI-272 is an inhibitor of EGFR, HER2/neu (ErbB2),
and HER3 (ErbB3) that irreversibly binds to and inhibits
these kinases at nanomolar concentrations.20 HKI-272 is
known to bind covalently to cysteine 805 in the EGFR kinase
domain.20 Preliminary cell culture data showed that HKI-272,
like other irreversible EGFR kinase inhibitors, can inhibit the
H1975 cell line that bears both the EGFR L858R erlotinib/
gefitinib-sensitizing mutation and EGFR T790M, which is
associated with acquired resistance.17 Furthermore, in a trans-
genic mouse model of EGFR L858R NSCLC, HKI-272 can
lead to tumor regressions.4 As a result of theoretical advan-
tages associated with its dual inhibition of EGFR and HER2,
HKI-272 was being pursued before our understanding of the
biology of EGFR inhibitor response or acquired resistance to
EGFR TKIs.
Kwak and colleagues performed the phase I trial of
HKI-272 in patients with advanced solid tumors who had
evidence of expression (determined by immunohistochemical
analysis) of either EGFR or HER2.21 In this phase I trial,
including mostly patients with metastatic breast cancer and
NSCLC, the maximum tolerated dose was 320 mg. Diarrhea
was the dose-limiting toxic effect and most common adverse
event. Rash was uncommon. In the initial report of this phase
I trial, the response rate among patients with breast cancer
was 30% (7/23). With just 12 patients with NSCLC enrolled,
no radiographic partial responses were observed, but five
patients with previous progression of disease taking erlotinib
or gefitinib had stable disease for more than 24 weeks while
taking HKI-272.
Based on the in vitro kinase inhibition profile and
encouraged by preliminary data from the phase I trial, a
3-arm phase II trial of HKI-272 in patients with NSCLC was
conducted (Figure 1). All patients were required to have
tumor tissue available for mutational analysis before enroll-
ment in the clinical trial. Patients with previous treatment
with erlotinib or gefitinib for more than 3 months were
allocated to one of two arms based on the presence or absence
of drug-sensitizing EGFR mutations. The third arm accrued
patients who had received no prior therapy for NSCLC but
had clinical characteristics associated with response to ge-
fitinib or erlotinib (i.e., patients who had smoked less than 15
pack-years who had adenocarcinoma). Enrollment in this
clinical trial is complete, but preliminary results have not
been reported.
XL647
XL647 (EXEL-7647; Exelixis Inc, San Francisco, Cal-
ifornia) inhibits EGFR, HER2, vascular endothelial growth
factor receptor (VEGFR) 2, Flt-4, and EphB4 at nanomolar
concentrations.22 Although it is a reversible inhibitor of
EGFR, like erlotinib and gefitinib, its broader spectrum of
inhibition raised the possibility that it may have properties
that will allow the drug to overcome acquired resistance to
erlotinib or gefitinib. In cell culture and tumor xenograft
experiments that use the H1975 cell line (which bears EGFR
with both L858R and T790M mutations), treatment with
XL647 shows a half maximal inhibitory concentration (IC50)
that is more than 10-fold lower than that observed with
erlotinib or gefitinib. Although the precise mechanism by
which XL647 inhibits this cell line is unclear, down-regula-
tion of both AKT and ERK occurs.
In phase I trials, XL647 has been studied using two
different dosing schema, an intermittent schedule with 5 days
of treatment every 14 days and a continuous schedule.23,24
The preliminary results of the phase I trial of the intermittent
schedule were reported after 40 patients had been treated.24
The maximum tolerated dose (MTD) identified with the
intermittent dosing schedule was 4.68 mg/kg. The dose-
limiting toxic effect was diarrhea, with grade 3 diarrhea
observed in two patients treated at a dose level above the
MTD. Other significant toxic effects reported in this XL647
schedule were a grade 4 pulmonary embolism and an episode
of QT prolongation observed below the MTD. Grade 1 and
grade 2 rash, fatigue, and nausea were also observed. The
pharmacokinetic profile of a flat daily dose of 350 mg
resulted in a similar pharmacokinetic profile as the 4.68-
mg/kg dose, and the flat dose was used in further phase II
trials of this schedule. Twenty-six patients have been treated
with the continuous schedule of XL647, up to an MTD of 300
mg.23 The dose-limiting toxic effects observed were drug-
induced pneumonitis and two episodes of grade 2 QTc
prolongation. The most common treatment-related adverse
FIGURE 1. A schematic of the HKI-272 3-arm
phase II trial.
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events were grade 1 and grade 2 diarrhea, rash, fatigue, and
dysgeusia.
The first reported phase II trial of XL647 in patients
with NSCLC used the intermittent dosing schedule and en-
riched, using clinical characteristics, for patients most likely
to respond to EGFR inhibitors.25 For inclusion in this study,
patients must have had no prior systemic therapy for stage IV
NSCLC, an adenocarcinoma, and 1 of the following charac-
teristics: a history of smoking of less than 15 pack-years,
female sex, or Asian ethnicity. The preliminary data from this
phase II trial show a response rate of 29% (10/34). In patients
with tissue available, EGFR mutational analysis was per-
formed. Although 6 of the 10 patients with partial response
had EGFR mutations, 3 patients had wild-type EGFR. Of the
seven patients with classic EGFR mutations, six had a partial
response and one had prolonged stable disease. As in the
phase I trial, the most common adverse events were diarrhea,
rash, fatigue, and nausea, all grade 1 or grade 2. There were
episodes of asymptomatic prolongation of QTc, with eight
patients having grade 1 prolongation of QTc, eight patients
having grade 2 prolongation, and two patients having grade 3
QTc prolongation.
Based on the encouraging phase II data in patients with
untreated NSCLC and the cell culture data that showed that
XL647 can inhibit the H1975 cell line, a trial has recently
opened in which patients with NSCLC who have had prior
treatment with erlotinib or gefitinib for more than 3 months
and who developed progressive disease are treated with
continuous XL647 (Clinicaltrials.gov NCT00522145). In ad-
dition, the upfront treatment phase II trial that uses clinical
characteristics to enrich for patients with EGFR mutations
will be expanded to include a cohort of patients treated with
a continuous dosing schedule.
BIBW2992
BIBW2992 is an irreversible inhibitor of EGFR and
HER2 with a lower IC50 than HKI-272.26 Preliminary results
are available for a phase I trial of BIBW2992 conducted in
the United Kingdom.26 The investigators have reported on the
results of treatment of 53 patients, of whom 15 had NSCLC.
The MTD was 50 mg/day. The dose-limiting toxic effects
were grade 3 dyspnea in one patient and grade 3 rash in two
patients. The most common adverse events seen were rash
and diarrhea. Preliminary efficacy data for the 15 patients
with NSCLC included an overall response rate of 20% (3/15).
A response was seen in 1 patient at the 10-mg dose level in
addition to 2 other responses seen at 40 mg. These patients
have continued on study for 12, 20, and 24 months. Two of
the three patients with response to BIBW2992 had EGFR
exon 19 deletions.
BIBW2992 is being further explored in a number of
trials worldwide. In the United States, in addition to clinical
trials in breast cancer, there is an ongoing trial that is
enrolling patients with stage IIIB or IV NSCLC who have
known activating EGFR mutations and have received prior
chemotherapy for NSCLC but have not received prior erlo-
tinib or gefitinib (Clinicaltrials.gov NCT00525148).
CONCLUSIONS
Although erlotinib and gefitinib have been the most
successful single-agent targeted therapies used in the treat-
ment of lung cancer, the problems of primary resistance and
acquired resistance to this class of drugs have highlighted
opportunities for newer drugs to block this pathway. A wide
variety of newer TKIs that act against EGFR and other targets
such as HER2 and vascular endothelial growth factor receptor
are now in early clinical development. They are being tested
both in the initial treatment of NSCLC and in patients who
have had prior treatment with, and demonstrated resistance
to, first-generation EGFR TKIs gefitinib and erlotinib.
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